Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Chromatin Plasticity Characterizes the Embryonic Stem Cell Nucleus

By LabMedica International staff writers
Posted on 02 Aug 2012
A recent paper presented new insights into the mechanisms that control chromatin plasticity in human embryonic stem cells and that allow these cells to differentiate in to many different types of tissue.

Investigators at the Hebrew University of Jerusalem (Israel) employed molecular, microscopic, and genomic approaches to compare the nature of chromatin (DNA, RNA, and protein) in embryonic stem cells (ESCs) to that found in mature, differentiated cells.

They reported in the June 19, 2012, issue of the journal Nature Communications that the use of epigenetic drugs and mutant ESCs lacking various chromatin proteins revealed that histone acetylation, G9a-mediated histone H3 lysine 9 (H3K9) methylation, and lamin A expression, all affected chromatin protein dynamics. More...


Histone acetylation controlled, almost exclusively, euchromatin protein dynamics. Euchromatin comprises the most active portion of the genome within the cell nucleus. It is a lightly packed form of chromatin that is rich in gene concentration, and is often under active transcription.

Lamin A expression regulates heterochromatin protein dynamics. Heterochromatin is tightly coiled chromosomal material that stains deeply during interphase and is believed to be genetically inactive. In differentiated cells, lamin A binds compacted domains of chromatin and anchors them to the cell’s nuclear envelope. Lamin A was not found in ESCs, which seems to generate a more dynamic chromatin state in the ESC nucleus.

G9a, the histone-lysine N-methyltransferase also known as H3 lysine-9 specific 3, regulates both euchromatin and heterochromatin protein dynamics.

In contrast, the investigators found that DNA methylation and nucleosome repeat length had little or no effect on chromatin-binding protein dynamics in ESCs. Altered chromatin dynamics associated with perturbed ESC differentiation.

“If we can apply this new understanding about the mechanisms that give embryonic stem cells their plasticity, then we can increase or decrease the dynamics of the proteins that bind DNA and thereby increase or decrease the cells’ differentiation potential,” said senior author Dr. Eran Meshorer, professor of genetics at the Hebrew University of Jerusalem. “This could expedite the use of embryonic stem cells in cell therapy and regenerative medicine, by enabling the creation of cells in the laboratory which could be implanted in humans to cure diseases characterized by cell death, such as Alzheimer's, Parkinson's, diabetes, and other degenerative diseases.”

Related Links:

Hebrew University of Jerusalem




Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Laboratory Software
ArtelWare
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.